Osamu Handa

Prof. Osamu Handa

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
SKSatoshi Kokura
Satoshi Kokura
OHOsamu Handa
Osamu Handa
TTTomohisa Takagi
Tomohisa Takagi
TITakeshi Ishikawa
Takeshi Ishikawa
YNYuji Naito
Yuji Naito
TYToshikazu Yoshikawa
Toshikazu Yoshikawa

20 May 2019 in Helicobacter
Verified
Journal Article
Open access
PDF file
MKMototsugu Kato
Mototsugu Kato
HOHiroyoshi Ota
Hiroyoshi Ota
MOMasumi Okuda
Masumi Okuda
SKShogo Kikuchi
Shogo Kikuchi
KSKiichi Satoh
Kiichi Satoh
STShin'Ichi Takahashi
Shin'Ichi Takahashi
Background: Since “Helicobacter pylori (H. pylori) infection” was set as the indication in the Japanese Society for Helicobacter Research (JSHR) Guidelines 2009, eradication treatment for H. pylori gastritis is covered under insurance since 2013 in Japan, and the number of H. pylori eradication has rapidly increased. Under such circumstances, JSHR has made the third revision to the “Guidelines for diagnosis and treatment of H. pylori infection” for the first time in 7 years.Methods: The Guideline Committee held 10 meetings. Articles published between the establishment of the 2009 Guidelines and March 2016 were reviewed and classified according to the evidence level; the statements were revised on the basis of this review. After inviting public comments, the revised statements were finalized using the Delphi method.Results: There was no change in the basic policy that H. pylori infectious disease is an indication for eradication. Other diseases presumed to be associated with H. pylori infection were added as indications. Serum pepsinogen level, endoscopic examination, and X‐ray examination were added to the diagnostic methods. The effects of 1‐week triple therapy consisting of potassium‐competitive acid blocker (P‐CAB), amoxicillin, and clarithromycin have improved, and high eradication rates can also be expected with proton pump inhibitors (PPI) or P‐CAB combined with amoxicillin and metronidazole. If the susceptibility test is not performed, the triple PPI or P‐CAB/amoxicillin/metronidazole therapy should be chosen, because the PPI/amoxicillin/metronidazole combination demonstrated a significantly higher eradication rate than PPI/amoxicillin/clarithromycin. In the proposal for gastric cancer prevention, we divided gastric cancer prevention measures by age from adolescent to elderly, who are at an increased gastric cancer risk, and presented measures for gastric cancer prevention primarily based on H. pylori eradication.Conclusion: We expect the revised guidelines to facilitate appropriate interventions for patients with H. pylori infection and accomplish its eradication and prevention of gastric cancer.

20 June 2018 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
TTTomohisa Takagi
Tomohisa Takagi
YNYuji Naito
Yuji Naito
RIRyo Inoue
Ryo Inoue
SKSaori Kashiwagi
Saori Kashiwagi
KUKazuhiko Uchiyama
Kazuhiko Uchiyama
YIYoshito Itoh
Yoshito Itoh

5 September 2010 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
OHOsamu Handa
Osamu Handa
YNYuji Naito
Yuji Naito
TYToshikazu Yoshikawa
Toshikazu Yoshikawa

23 April 2010 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
TTTomohisa Takagi
Tomohisa Takagi
Yuji NaitoYuji Naito
Yuji Naito
KMKatsura Mizushima
Katsura Mizushima
IHIkuhiro Hirata
Ikuhiro Hirata
NYNobuaki Yagi
Nobuaki Yagi
TYToshikazu Yoshikawa
Toshikazu Yoshikawa

1 August 2007 in Atherosclerosis
Verified
Journal Article
Closed access
RPRosaria Piga
Rosaria Piga
YNYuji Naito
Yuji Naito
SKSatoshi Kokura
Satoshi Kokura
OHOsamu Handa
Osamu Handa
TYToshikazu Yoshikawa
Toshikazu Yoshikawa